5-(4-氯苯基磺酰基)-喹唑啉-2,4-二胺 | 168910-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5-(4-氯苯基磺酰基)-喹唑啉-2,4-二胺
• 英文名称: 5-(4-chlorophenylsulfanyl)-quinazoline-2,4-diamine
• 英文别名: 2,4-Diamino-5-(4-chlorophenylthio)quinazoline；5-[(4-Chlorophenyl)sulfanyl]quinazoline-2,4-Diamine；5-(4-chlorophenyl)sulfanylquinazoline-2,4-diamine
• CAS: 168910-48-3
• 化学式: C₁₄H₁₁ClN₄S
• 分子量: 302.787
• InChiKey: AVRPDIOCAAWICH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-氯苯基磺酰基)-喹唑啉-2,4-二胺 在 potassium permanganate 、 溶剂黄146 、 氨 作用下， 以 水 为溶剂， 生成 5-(4-chlorobenzenesulfonyl)quinazoline-2,4-diamine
  参考文献：
  名称：

  [EN] 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY
  [FR] 2,4-DIAMINOQUINAZOLINES UTILES POUR LE TRAITEMENT D'UNE ATROPHIE MUSCULAIRE SPINALE

  摘要：

  2,4-二氨基喹唑啉的化学式I-IV和VI（I，II，III，IV和VI）可用于治疗脊髓性肌萎缩症（SMA）。

  公开号：

  WO2005123724A1
• 作为产物：
  描述：

  2,6-二氟苯腈 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 、 异丁酰胺 为溶剂， 反应 11.0h， 生成 5-(4-氯苯基磺酰基)-喹唑啉-2,4-二胺
  参考文献：
  名称：

  [EN] 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY
  [FR] 2,4-DIAMINOQUINAZOLINES UTILES POUR LE TRAITEMENT D'UNE ATROPHIE MUSCULAIRE SPINALE

  摘要：

  2,4-二氨基喹唑啉的化学式I-IV和VI（I，II，III，IV和VI）可用于治疗脊髓性肌萎缩症（SMA）。

  公开号：

  WO2005123724A1

文献信息

• Formulations for hydrophobic pharmaceutical agents
  申请人：——

  公开号：US20010012844A1

  公开（公告）日：2001-08-09

  The present invention features formulations, including liquid, semi-solid or solid pharmaceutical formulations, that improve the oral bioavailability of hydrophobic pharmaceutical agents, such as quinazoline-, nitrothiazole-, and indolinone-based compounds. Also featured are formulations for parenteral delivery of such hydrophobic pharmaceutical agents, as well as methods of making and using both types of formulations.

  本发明涉及包括液体、半固体或固体制剂的配方，可以提高疏水性药物，如喹唑啉、硝基噻唑和吲哚酮类化合物的口服生物利用度。还包括适用于静脉注射递送这些疏水性药物的配方，以及制备和使用这两种类型配方的方法。
• Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
  申请人：——

  公开号：US20010014679A1

  公开（公告）日：2001-08-16

  The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.

  本发明部分涉及使用基于喹唑啉的化合物调节丝氨酸/苏氨酸蛋白激酶功能的方法。该方法包括表达丝氨酸/苏氨酸蛋白激酶（例如RAF）的细胞。此外，本发明还描述了使用本发明所确定的化合物预防和治疗有关丝氨酸/苏氨酸蛋白激酶的异常情况的方法。此外，本发明还涉及喹唑啉化合物和包含这些化合物的制药组合物。
• 2,4-diaminoquinazolines for spinal muscular atrophy
  申请人：Singh Jasbir

  公开号：US20050288314A1

  公开（公告）日：2005-12-29

  2,4-Diaminoquinazolines of formulae I-IV and VI are useful for treating spinal muscular atrophy (SMA).

  公式I-IV和VI的2,4-二氨基喹唑啉可用于治疗脊髓肌肉萎缩症(SMA)。
• 2,4-Diaminoquinazolines for Spinal Muscular Atrophy
  申请人：Singh Jasbir

  公开号：US20110112118A1

  公开（公告）日：2011-05-12

  2,4-Diaminoquinazolines of formulae I-IV and VI are useful for treating spinal muscular atrophy (SMA).

  公式I-IV和VI的2,4-二氨基喹唑啉化合物可用于治疗脊髓性肌萎缩症（SMA）。
• Selective Inhibitors of Candida albicans Dihydrofolate Reductase: Activity and Selectivity of 5-(Arylthio)-2,4-diaminoquinazolines
  作者：Joseph H. Chan、Jean S. Hong、Lee F. Kuyper、David P. Baccanari、Suzanne S. Joyner、Robert L. Tansik、Christine M. Boytos、Sharon K. Rudolph

  DOI：10.1021/jm00018a021

  日期：1995.9

  The recent increase in fungal infections, especially among AIDS patients, has resulted in the need for more effective antifungal agents. In our search for such agents, we focused on developing compounds which inhibit fungal dihydrofolate reductase (DHFR). A series of 25 5-(arylthio)-2,4-diaminoquinazolines were synthesized as potentially selective inhibitors of Candida albicans DHFR. The majority of the compounds were potent inhibitors of C. albicans DHFR and much less active against human DHFR. High selectivity, as defined by the ratio of the I-50 values for human and C. albicans DHFR, was achieved by compounds with bulky and rigid 4-substituents in the phenylthio moiety. For example, 5-[(4-morpholinophenyl)thio]-2,4-diaminoquinazoline displayed a selectivity ratio of 540 and was the most selective inhibitor synthesized to date. Substitution in the 2- or 3-position of the 5-phenylthio group provided only marginal selectivity. 6-Substituted-5-[(4-tert-butylphenyl)thio]-2,4-diaminoquinazolines showed potent activity against the C. albicans enzyme but were equally active against human DHFR. Most of the selective compounds were also good inhibitors of C. albicans cell growth, with minimum inhibitory concentration values as low as 0.05 mu g/mL.